Sopharma AD-Sofia (XBUL:SFA) Beta: N/A (As of Jul. 01, 2026)


XBUL:SFA Sopharma AD-Sofia XBUL:SFA
59 GF Score
Price €1.93
GF Value €3.16
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Sopharma AD-Sofia's Beta is Not available.

Sopharma AD-Sofia  (XBUL:SFA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Sopharma AD-Sofia Beta Related Terms

Sopharma AD-Sofia Beta Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Beta Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:SFA
59GF Score
Sopharma AD-Sofia XBUL:SFA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Sopharma AD-Sofia (XBUL:SFA) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of €1.93 is trading 38.9% below its estimated GF Value™ of €3.16. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for XBUL:SFA:

  • Beta: N/A
  • GF Value™: €3.16 vs. price of €1.93 (38.9% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the XBUL:SFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:Poland3JR:Germany
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
59GF Score

Get the complete analysis for XBUL:SFA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€3.16
GF Value